José Luis Díaz-Díaz (Jose L Díaz-Díaz)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Magnetic Resonance

Low Density Lipoprotein

Cardiovascular Disease

Coronary Artery

Top Venues

Circulation. Cardiovascular imaging

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Leopoldo Pérez de Isla, José Luis Díaz-Díaz, Manuel J Romero-Jimenez, Ovidio Muñiz-Grijalvo, Juan D Mediavilla, Rosa Argüeso, Raimundo de Andrés, Francisco Fuentes-Jimenez, Juan F Sánchez Muñoz-Torrero, Patricia Rubio Marín, Pilar Álvarez-Baños, Dolores Mañas, Lorena Suárez Gutierrez, Adriana Saltijeral Cerezo, Pedro Mata, null null
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation. Cardiovascular imaging (2024)
Leopoldo Pérez de Isla, José Luis Díaz-Díaz, Manuel J Romero-Jimenez, Ovidio Muñiz-Grijalvo, Juan D Mediavilla, Rosa Argüeso, Raimundo de Andrés, Francisco Fuentes-Jimenez, Juan F Sánchez Muñoz-Torrero, Patricia Rubio Marín, Pilar Álvarez-Baños, Dolores Mañas, Lorena Suárez Gutierrez, Adriana Saltijeral Cerezo, Pedro Mata, null null
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation. Cardiovascular imaging 17 (1) (2024)
Leopoldo Pérez de Isla, José Luis Díaz-Díaz, Manuel J Romero-Jimenez, Ovidio Muñiz-Grijalvo, Juan D Mediavilla, Rosa Argüeso, Raimundo de Andrés, Francisco Fuentes-Jimenez, Juan F Sánchez Muñoz-Torrero, Patricia Rubio Marín, Pilar Álvarez-Baños, Dolores Mañas, Lorena Suárez Gutierrez, Adriana Saltijeral Cerezo, Pedro Mata, null null
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation. Cardiovascular imaging 17 (1) (2024)
Leopoldo Pérez de Isla, José Luis Díaz-Díaz, Manuel J Romero-Jimenez, Ovidio Muñiz-Grijalvo, Juan D Mediavilla, Rosa Argüeso, Raimundo de Andrés, Francisco Fuentes-Jimenez, Juan F Sánchez Muñoz-Torrero, Patricia Rubio Marín, Pilar Álvarez-Baños, Dolores Mañas, Lorena Suárez Gutierrez, Adriana Saltijeral Cerezo, Pedro Mata, null null
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study. Circulation. Cardiovascular imaging 17 (1) (2024)
Pere Rehues, Josefa Girona, Montse Guardiola, Núria Plana, Francesco Purrello, Salvatore Piro, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Lluís Recasens, Marta Pinyol, Roser Rosales, Yaiza Esteban, Nuria Amigo, Lluis Masana, Daiana Ibarretxe, Josep Ribalta
PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. International journal of molecular sciences 24 (3) (2023)
Pere Rehues, Josefa Girona, Montse Guardiola, Núria Plana, Francesco Purrello, Salvatore Piro, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Lluís Recasens, Marta Pinyol, Roser Rosales, Yaiza Esteban, Nuria Amigo, Lluis Masana, Daiana Ibarretxe, Josep Ribalta
PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. International journal of molecular sciences 24 (3) (2023)
Leopoldo Pérez de Isla, José Luis Díaz-Díaz, Manuel J Romero-Jimenez, Ovidio Muñiz-Grijalvo, Juan D Mediavilla, Rosa Argüeso, Juan F Sánchez Muñoz-Torrero, Patricia Rubio Marín, Pilar Álvarez-Baños, Paola Helena Ponte Márquez, Dolores Mañas, Lorena Suárez Gutierrez, José María Cepeda, Marta Casañas, Francisco Fuentes-Jimenez, Carlos Guijarro Herraiz, Miguel Ángel Barba, Adriana Saltijeral Cerezo, Teresa Padró, Pedro Mata, null null
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study. Circulation (2023)
Pere Rehues, Josefa Girona, Montse Guardiola, Núria Plana, Francesco Purrello, Salvatore Piro, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Lluís Recasens, Marta Pinyol, Roser Rosales, Yaiza Esteban, Nuria Amigo, Lluis Masana, Daiana Ibarretxe, Josep Ribalta
PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. International journal of molecular sciences 24 (3) (2023)